Modeling human tumors

CAMBRIDGE, Mass.—At the recent AACR meeting, AVEO Pharmaceuticals announced the development of fully human breast tumors in mice

Register for free to listen to this article
Listen with Speechify
CAMBRIDGE, Mass.—At the recent meeting of the American Association for Cancer Research, AVEO Pharmaceuticals announced the development of the first platform for the generation of fully human breast tumors in mice. According to company scientists, the Human-in-Mouse (HIM) system is a significant improvement over current xenograph models of human breast cancer and should facilitate more realistic efficacy studies in preclinical drug testing.
Dr. Murray Robinson, AVEO's vice president of oncology, presented the HIM model system as part of a symposium titled: Modeling Abnormal Proliferation in Model Organisms. "As we further develop our portfolio of novel oncology products, such as AV-412, the HIM system and AVEO's proprietary Human Response Prediction platform will help us design clinical trials with a higher likelihood of success," said Tuan Ha-Ngoc, president and CEO of AVEO.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue